Innate Pharma/$IPHA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Innate Pharma
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
Ticker
$IPHA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
181
ISIN
US45781K2042
Website
Innate Pharma Metrics
BasicAdvanced
$163M
-
-$0.71
0.94
-
Price and volume
Market cap
$163M
Beta
0.94
52-week high
$2.59
52-week low
$1.29
Average daily volume
14K
Financial strength
Current ratio
2.6
Quick ratio
2.499
Long term debt to equity
252.275
Total debt to equity
350.86
Interest coverage (TTM)
-91.12%
Profitability
EBITDA (TTM)
-57.92
Gross margin (TTM)
-158.34%
Net profit margin (TTM)
-245.87%
Operating margin (TTM)
-256.32%
Revenue per employee (TTM)
$128,490
Management effectiveness
Return on assets (TTM)
-22.52%
Return on equity (TTM)
-162.91%
Valuation
Price to revenue (TTM)
6.121
Price to book
14.35
Price to tangible book (TTM)
13.9
Price to free cash flow (TTM)
-16.902
Free cash flow yield (TTM)
-5.92%
Free cash flow per share (TTM)
-10.50%
Growth
Revenue change (TTM)
-67.36%
Earnings per share change (TTM)
548.69%
3-year revenue growth (CAGR)
-6.61%
10-year revenue growth (CAGR)
10.19%
3-year earnings per share growth (CAGR)
-2.76%
10-year earnings per share growth (CAGR)
4.53%
What the Analysts think about Innate Pharma
Analyst ratings (Buy, Hold, Sell) for Innate Pharma stock.
Innate Pharma Financial Performance
Revenues and expenses
Innate Pharma Earnings Performance
Company profitability
Innate Pharma News
AllArticlesVideos
Innate Pharma Announces Its Participation in H.C. Wainwright and Wolfe Research Healthcare Conferences
Business Wire·1 week ago
Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress
Business Wire·2 weeks ago
Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Innate Pharma stock?
Innate Pharma (IPHA) has a market cap of $163M as of June 26, 2025.
What is the P/E ratio for Innate Pharma stock?
The price to earnings (P/E) ratio for Innate Pharma (IPHA) stock is 0 as of June 26, 2025.
Does Innate Pharma stock pay dividends?
No, Innate Pharma (IPHA) stock does not pay dividends to its shareholders as of June 26, 2025.
When is the next Innate Pharma dividend payment date?
Innate Pharma (IPHA) stock does not pay dividends to its shareholders.
What is the beta indicator for Innate Pharma?
Innate Pharma (IPHA) has a beta rating of 0.94. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.